The specific CXCR4 antagonist AMD3100 has been approved by the FDA for the autologous transplantation of bone marrow cells in patients with non-Hodgkin's lymphoma or multiple myeloma 28. The gene discussed is CXCR4; the disease is plasma cell myeloma.